Replimune Group (NASDAQ:REPL) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Replimune Group (NASDAQ:REPL - Free Report) in a report released on Thursday,Benzinga reports. They currently have a $22.00 price objective on the stock.

Several other equities research analysts have also recently weighed in on the stock. Piper Sandler increased their target price on shares of Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday, June 2nd. Cantor Fitzgerald started coverage on Replimune Group in a report on Friday, June 20th. They issued an "overweight" rating for the company. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $20.83.

Replimune Group Stock Performance

REPL traded down $0.10 during trading on Thursday, hitting $9.45. The stock had a trading volume of 581,094 shares, compared to its average volume of 865,323. The firm has a market cap of $728.50 million, a PE ratio of -3.08 and a beta of 0.61. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.17. Replimune Group has a 12 month low of $6.44 and a 12 month high of $17.00. The company has a 50 day simple moving average of $9.04 and a 200-day simple moving average of $10.58.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the company earned ($0.25) earnings per share. Analysts expect that Replimune Group will post -2.97 EPS for the current year.

Insiders Place Their Bets

In related news, Director Philip Astley-Sparke sold 32,279 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the transaction, the director directly owned 1,405,071 shares of the company's stock, valued at $11,324,872.26. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Sushil Patel sold 25,105 shares of the stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $202,346.30. Following the sale, the chief executive officer directly owned 343,576 shares in the company, valued at approximately $2,769,222.56. This represents a 6.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,907 shares of company stock worth $603,655 over the last ninety days. 8.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC boosted its holdings in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after buying an additional 1,655 shares during the last quarter. US Bancorp DE increased its stake in Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after purchasing an additional 3,921 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd raised its holdings in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after purchasing an additional 8,183 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Replimune Group by 897.2% during the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after purchasing an additional 7,913 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.